By 2030, it is anticipated that the Singapore infectious disease therapeutics market will reach a value of $211.71 Mn from $143.84 Mn in 2022, growing at a CAGR of 5% during 2022-30. The Infectious Disease Therapeutics in Singapore is dominated by a few domestic pharmaceutical companies such as A*STAR Institute, Temasek Life Sciences Laboratory and Acumen Research Laboratories. The Infectious Disease Therapeutics market in Singapore is segmented into different therapeutic areas and different disease types. The major factors affecting the Singapore infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Singapore.
By 2030, it is anticipated that the Singapore infectious disease therapeutics market will reach a value of $211.71 Mn from $143.84 Mn in 2022, growing at a CAGR of 5% during 2022-30.
Singapore is a high-income, developing island country off the southern tip of the Malay Peninsula in Southeast Asia. The Infectious Illnesses Act (IDA), which was passed by Parliament in 1976 and went into effect on August 1, 1977, is Singapore's primary piece of law dealing with the prevention and control of infectious diseases. The Ministry of Health and the National Environment Agency (NEA) jointly manage this act.
According to Singapore's weekly bulletin for February 2023, the most common infectious diseases in the area are salmonellosis, campylobacteriosis, dengue fever, and severe diarrhea. Singapore's government spends 6.1% of its GDP on healthcare.
Market Growth Drivers Analysis
Singapore is well-known for its high healthcare standards, with a focus on disease prevention and management. As a result, there is an increasing need for efficient therapies for infectious diseases. To strengthen the healthcare sector, the Singaporean government has been investing in healthcare infrastructure and encouraging healthcare initiatives. This includes infectious disease initiatives like the National HIV/AIDS Program and the National Tuberculosis Control Program. The strategic location of Singapore as a pharmaceutical and biotech centre has attracted significant investment in the infectious disease treatment sector. These aspects could boost Singapore's infectious disease therapeutics market.
Market Restraints
Singapore's regulatory climate can be difficult for pharmaceutical businesses, with stringent standards for clinical trials and data submission, as well as a lengthy approval procedure for new products. Singapore is confronted with difficulties such as skilled labour and housing constraints, as well as an ageing population. It is heavily reliant on exports and imports. These factors may deter new entrants into the Singapore infectious disease therapeutics market.
Key Players
June 2022: SCG Cell Therapy Pte Ltd, a leading biotechnology company based in Singapore, said today that it has struck a collaboration agreement with A*STAR's Institute of Molecular and Cell Biology (IMCB) to accelerate the clinical translation of its cell-based immunotherapy pipeline. SCG will contribute its patented technology to the therapeutic development of immune cell-based therapy candidates such as CAR-T, TCR-T therapies, antibodies, and vaccines as part of this agreement.
The Health Sciences Authority (HSA) and the Ministry of Health are largely in charge of the regulation and reimbursement of infectious disease medicines in Singapore (MOH). The national health insurance programme, known as the MediShield Life plan, oversees the payment procedure for infectious disease treatments in Singapore.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Singapore infectious disease therapeutics market will reach a value of $211.71 Mn from $143.84 Mn in 2022, growing at a CAGR of 5% during 2022-2030.
In Singapore, the regulation and reimbursement of infectious disease therapeutics are primarily overseen by the Health Sciences Authority (HSA), MediShield Life scheme and the Ministry of Health (MOH).
The Infectious Disease Therapeutics in Singapore is dominated by a few domestic pharmaceutical companies such as A*STAR Institute, Temasek Life Sciences Laboratory and Acumen Research Laboratories.